ArticleCell death & disease2026
Spatiotemporal mapping of CD112 unveils its dichotomous role in T-cell exhaustion and ferroptosis crosstalk in cervical cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD112 emerges as a novel immune checkpoint (IC) in various malignancies, its spatial biology and dual mechanisms in cervical cancer (CC) progression are unexplored. This study systematically analyzes the dual-functions of CD112 in immune evasion and metabolic adaptation in CC. Proteomics and immune checkpoint analysis were performed on 10 CC and normal tissues to explore key targets. Multiplex immunofluorescence (mIHC) on 318 CC tissue microarrays analyzed CD112/CD112R spatial distribution and prognosis. Tumor cell and T cell co-culture models and immunocompetent murine models were used to validate effects of anti-CD112 mAb±anti-PD-1 treatment. CD112 expression in the infiltrated and margine areas correlated with PD-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.